Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537309 | 1.00 | CA1 (0.56) | CA1CA2GAADRD2POLB | |
| SCHEMBL17133738 | 0.88 | CA1 (0.49) | CA1CA2DRD2MAPTKMT2A | |
| SCHEMBL17537311 | 0.88 | CA1 (0.49) | CA1CA2DRD2MAPTKMT2A | |
| SCHEMBL2928288 | 0.86 | CTSL (0.48) | CA1CA2GAADRD2BRD4 | |
| SCHEMBL2931394 | 0.85 | MEN1 (0.52) | CA1CA2GAAMAPTKMT2A | |
| SCHEMBL24011136 | 0.81 | GAA (0.58) | CA1CA2GAADRD2BRD4 | |
| SCHEMBL3584002 | 0.80 | CTSK (0.50) | CA1CA2GAAMAPTKMT2A | |
| SCHEMBL2921238 | 0.80 | CTSK (0.50) | CA1CA2GAAMAPTKMT2A | |
| SCHEMBL6347286 | 0.79 | GAA (0.72) | CA1CA2GAADRD2KMT2A | |
| SCHEMBL14609955 | 0.78 | GAA (0.57) | CA1CA2GAADRD2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2927212-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | Kyoto University (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KDM1A, DOT1L, KDM1B | CA1 3293/4885CA2 2062/4885GAA 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.